Akèy › Poliradikiloneyropati demyelinizan enflamatwa kwonik › Kalifòni › Indio
Etid klinik pou Poliradikiloneyropati demyelinizan enflamatwa kwonik nan Indio, CA
5 etid pou Poliradikiloneyropati demyelinizan enflamatwa kwonik ap chèche patisipan nan sit nan ak bò kote Indio (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Ap rekriteFaz 2
- Site Number - 1607, Rancho Mirage · 11 mi lwen
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Ap rekriteFaz 3
- Samir Macwan, M.D., Inc. (S corporation), Rancho Mirage · 11 mi lwen
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Ap rekriteFaz 3
- Samir Macwan, M.D., Inc., Rancho Mirage · 11 mi lwen
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Ap rekriteFaz 3
- GC2402 Study Site 104, Rancho Mirage · 11 mi lwen
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Ap rekriteEtid obsèvasyon
- Samir Macwan MD Inc, Rancho Mirage · 11 mi lwen
Etid Poliradikiloneyropati demyelinizan enflamatwa kwonik nan lòt vil
- New York City, NY7 etid
- Miami, FL6 etid
- Houston, TX6 etid
- Kansas City, KS5 etid
- Philadelphia, PA5 etid
- New Haven, CT5 etid
- St. Louis, MO5 etid
- Tampa, FL4 etid
- Cleveland, OH4 etid
- Milwaukee, WI4 etid
- Washington, DC4 etid
- Birmingham, AL4 etid
Lòt etid nan Indio
- Kansè nan tete6 etid
- Obèsite5 etid
- Sipwa5 etid
- Osteoartrit jenou4 etid
- Kansè pwostat3 etid
- Kansè Poumon ki pa ti selil3 etid
- Kansè poumon3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.